U.S. charges Teva in generic drugs price-fixing probe
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Jana Partners Takes New Stake in Teva, Cheering Cost-Cut Plans - Bloomberg
Teva: Warren Buffett Messed Things Up For Short-Sellers - Bloomberg
Teva Seeking to Break Its Streak of Post-Earnings Stock Losses - Bloomberg
Kare Schultz, president and chief executive officer of Teva... News Photo - Getty Images
Meet the Women of Bloomberg TV
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York state | CNN
Teva Pharmaceutical Industries
Teva Considers 10,000 Job Cuts - Bloomberg
Teva closes in on Allergan's generics unit
Watch Teva CEO on Second-Quarter, Potential DOJ Settlement - Bloomberg
Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg
Teva's U.S. Unit Charged in Generic-Drug Price-Fixing Probe - Bloomberg
Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict - Bloomberg
Teva (TEVA), AbbVie (ABBV) to Pay $161.5 Million in West Virginia Opioid Case - Bloomberg
Teva (TEVA) Explores Sale of $2 Billion Active Ingredients Unit - Bloomberg
Teva's job-cut tally could touch 10K: report | Fierce Pharma
Teva Is at Center of Drug Price-Fixing Case Filed by States - Bloomberg
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters
Teva makes $40B offer for Mylan | The Arkansas Democrat-Gazette - Arkansas' Best News Source
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
